ReviewJournal of molecular medicine (Berlin, Germany)2012
Circulating microRNAs: novel biomarkers for cardiovascular diseases.
Review in Journal of molecular medicine (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.Journal of molecular neuroscience : MN · 2018Pooled it
- Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017Trial
- Circulating microRNAs in Atrial Fibrillation: Clinical Significance and Future Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Upregulated miR-10b-5p as a potential miRNA signature in amyotrophic lateral sclerosis patients.Frontiers in cellular neuroscience · 2024Article
- Evaluation of microRNA Expression Features in Patients with Various Types of Arterial Damage: Thoracic Aortic Aneurysm and Coronary Atherosclerosis.Journal of personalized medicine · 2023Article
- Article
- Dysregulation of Serum MicroRNA after Intracerebral Hemorrhage in Aged Mice.Biomedicines · 2023Article
- Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban.Human genomics · 2022Article
- Circulating miRNA as potential biomarkers for diabetes mellitus type 2: should we focus on searching for sex differences?Journal of applied genetics · 2022Review
- Copeptin, miRNA-208, and miRNA-499 as New Biomarkers for Early Detection of Acute Coronary Syndrome.Applied biochemistry and biotechnology · 2022Review
- Elevated serum miR-133a predicts patients at risk of periprocedural myocardial injury after elective percutaneous coronary intervention.Cardiology journal · 2022Article
- Editorial: Novel Insight Into the Diagnosis and Treatment of Cardio(Thoracic) Diseases in Dogs and Cats.Frontiers in veterinary science · 2022Article
- Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study.Biomolecules · 2021Article
- Identification and Characterization of Circulating MicroRNAs as Novel Biomarkers in Dogs With Heart Diseases.Frontiers in veterinary science · 2021Article
- Expression Profile of Circulating MicroRNAs in Dogs With Cardiac Hypertrophy: A Pilot Study.Frontiers in veterinary science · 2021Article
- Resveratrol inhibits hypertrophic scars formation by activating autophagy via the miR-4654/Rheb axis.Molecular medicine reports · 2020Article
- Diabetes and COVID-19 risk: an miRNA perspective.American journal of physiology. Heart and circulatory physiology · 2020Review
- Blood microRNA 202-3p associates with the risk of essential hypertension by targeting soluble ST2.Bioscience reports · 2020Article
- Elevated Plasma Levels of Circulating Extracellular miR-320a-3p in Patients with Paroxysmal Atrial Fibrillation.International journal of molecular sciences · 2020Article
- Inhibition ofAging · 2020Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a novel class of small, non-coding, single-stranded RNAs that negatively regulate gene expression via translational inhibition or mRNA degradation followed by protein synthesis repression. Many miRNAs are expressed in a tissue- and/or cell-specific manner and their expression patterns are reflective of underlying patho-physiologic processes. miRNAs can be detected in serum or in plasma in a remarkably stable form, making them attractive biomarkers for human diseases. This review describes the progress of identifying circulating miRNAs as novel biomarkers for diverse cardiovascular diseases, including acute myocardial infarction, heart failure, coronary artery disease, diabetes, stroke, essential hypertension, and acute pulmonary embolism. In addition, the origin and function and the different strategies to identify circulating miRNAs as novel biomarkers for cardiovascular diseases are also discussed. Rarely has an opportunity arisen to advance such new biology for the diagnosis of cardiac diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.